FOXO4-DRI

A synthetic peptide built from D-amino acids in reverse order (a D-retro-inverso design) and fused to a cell-entry sequence from HIV-TAT. It was designed in 2017 to break the bond between FOXO4 and p53 inside senescent cells, which pushes those cells to self-destruct.

In mice it cleared senescent cells, countered chemotherapy toxicity and restored fur density, fitness and kidney function in fast-aging and naturally aged animals. In aged mice it also eased low testosterone and improved sperm quality. None of this has been tested in people.

No human dose exists. Community courses copy the mouse schedule: 3 doses every other day, most often 2 mg each, with reported ranges from 1 mg to 10 mg and some guides listing up to 25 mg. Then people stop for months.

In Baar et al. 2017: 5 mg per kg, 3 doses every other day (days 1, 3 and 5), into a vein for the chemotherapy (doxorubicin) mice and into the abdomen for naturally aged mice. The aged mice were assessed 30 days after the injections. It is the only published whole-animal regimen, it was never tested in people, and mouse doses do not carry over to humans by body weight.

Guides that convert by body surface area get roughly 25 mg per dose for a 60 kg adult or about 28.5 mg for 70 kg, far above what most users inject. One guide warns the conversion carries large uncertainty, and no human study has checked any of it.

Guides say 1 to 3 courses a year, with at least 4 to 6 months between them as the community consensus.

It is the most reported effect, usually a day or two after a dose. Guides attribute it to cleared cells and the debris they leave. That is a guess; nobody has measured senescent cell burden before and after in a user.

Guides use 1, 2 or 3 mL. 2 mL gives 5 mg per mL, so a 2 mg dose is 40 units; 3 mL suits small daily doses.

40 units on a U-100 insulin syringe when a 10 mg vial is mixed with 2 mL. With 1 mL it is 20 units.

Guides say about 28 days in the fridge at 2 to 8 C. Since a course is only 3 to 5 doses, most people finish a vial well inside that.

Never published. D-amino acids resist the enzymes that break down normal peptides, so guides expect it to last longer than most. In cell studies the peptide was still detectable inside senescent cells 72 hours later.

No. ClinicalTrials.gov lists no FOXO4-DRI study. Human data are limited to cells in a dish, such as expanded cartilage cells where it removed more than half of the cells in the most senescent batches.

In the 2017 mice it looked well tolerated: no change in body weight, platelets or heart tissue. One later mouse study found senolytics including FOXO4-DRI worsened pulmonary hypertension. Human safety is unknown.

No. It is not approved and is not on FDA's 503A bulk substance lists for compounding (May 2026 update). It is sold as a research chemical.

It is not named on the WADA 2026 list. The S0 class bans any substance without human approval, including drugs in pre-clinical development, which on its plain wording covers FOXO4-DRI.

Guides sequence instead of stacking: run FOXO4-DRI alone, wait 1 to 2 weeks, then start epitalon, GHK-Cu, MOTS-c or NAD+.

In fast-aging mice it brought back fur density. No human hair data exist.

One app's anonymous logs (28 reporters) show most doses at 2 mg or more per injection, with recovery and energy as the top picked benefits. These are self-reports, not evidence.